Melanoma
DermTech Q1 Revenues up 62 Percent
The firm processed approximately 9,400 billable samples in Q1, a 62 percent increase compared to approximately 5,800 samples in Q1 of 2020.
Castle Biosciences Q1 Revenues Up 31 Percent
The company said it delivered 11 percent fewer DecisionDx-Melanoma test results year over year, but that the total number of all tests delivered rose 4 percent.
Castle Biosciences Q4 Revenues Down 2 Percent
The skin cancer diagnostics company said it delivered 5 percent fewer DecisionDx-Melanoma test results in Q4 2020 than in the previous year's fourth quarter.
DermTech Using $144M Financing to Spur Marketing, Telemedicine Efforts For Molecular Melanoma Assay
Premium
The firm expects to increase commercial coverage for its pigmented lesion assay for melanoma while widening its pipeline to diagnose other varieties of skin cancer.
Oppenheimer Initiates Coverage of DermTech With Outperform Rating
In a survey, analysts found that reimbursement and test awareness were major barriers to driving adoption of the firm's assay for identifying skin cancer.